Recruiting
Phase 3

Tilrekimig

Sponsor:

Pfizer

Code:

NCT07839884

Conditions

Moderate to Severe Chronic Obstructive Pulmonary Disease

Eligibility Criteria

Sex: All

Age: 35 - 70+

Healthy Volunteers: Not accepted

Interventions

Tilrekimig

Study Details

Brief summary:

A Continuation Study of Tilrekimig in Adults with Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About this Medicine when Used for a Long Period of Time.

Conditions

Moderate to Severe Chronic Obstructive Pulmonary Disease

Study ID

NCT07839884

Start date

Oct 14, 2026

Status verified date

Nov, 2026

Completion date

Apr 21, 2034

Anticipated

Primary completion date

Apr 21, 2034

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 35 - 70+

Healthy Volunteers: Not accepted

INCLUSION CRITERIA

  • Participants who completed parent study C4531031.
  • Individuals of childbearing potential must be willing to use a highly effective method of contraception.

EXCLUSION CRITERIA

  • Ongoing safety-significant AE.
  • Parent-study SAE incompatible with continued participation.
  • Medical, laboratory, psychiatric, or behavioral condition that increases risk or interferes with study participation.
  • Pregnancy or breastfeeding.

Study Design

Enrollment

1360 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Tilrekimig (PF-07275315)

Tilrekimig (PF-07275315) subcutaneous injection (sc)

Interventions

Tilrekimig

SC injection

Primary outcome measure

  • Number of Participants With Treatment-Emergent Adverse Events During Treatment Period 1 (TP1) [ Time Frame: Up to 60 weeks ]
  • Number of Participants With Treatment-Emergent Serious Adverse Events During Treatment Period 1 [ Time Frame: Up to 60 weeks ]
  • Number of Participants With Treatment-Emergent Adverse Events Leading to Permanent Discontinuation of Study Intervention During Treatment Period 1 [ Time Frame: Up to 60 weeks ]
  • Number of Participants With Clinically Significant Laboratory Abnormalities During Treatment Period 1 [ Time Frame: Up to 60 weeks ]

Central Contacts and Locations

Central contacts

Locations

Institute of HealthCare Assessment d/b/a Apex Clinical Research

Recruiting

San Diego, California, United States, 92120

Southeastern Research Center

Recruiting

Winston-Salem, North Carolina, United States, 27103

Clinical Research Associates of Central PA

Recruiting

DuBois, Pennsylvania, United States, 15801

More Information

Sponsor

Pfizer

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Keywords

  • COPD

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Pfizer on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.